Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition

Irinotecan (CPT-11) has been tested as a single agent in several studies, and response rates of 18-23% have been reported in first-line gastric cancer therapy. In the present study we report the safety and efficacy results combining CPT-11 with 5-fluorouracil (5-FU) and folinic acid (FA). Thirty con...

Full description

Saved in:
Bibliographic Details
Published in:Tumori 2006-09, Vol.92 (5), p.379-383
Main Authors: Beretta, Elena, Di Bartolomeo, Maria, Buzzoni, Roberto, Ferrario, Erminia, Mariani, Luigi, Gevorgyan, Arpine, Bajetta, Emilio
Format: Article
Language:English
Subjects:
Adult
Aged
Antimetabolites, Antineoplastic - administration & dosage
Antineoplastic Agents, Phytogenic - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Camptothecin - administration & dosage
Camptothecin - analogs & derivatives
Disease-Free Survival
Drug Administration Schedule
Female
Fluorouracil - administration & dosage
Humans
Kaplan-Meier Estimate
Leucovorin - administration & dosage
Male
Middle Aged
Prospective Studies
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Irinotecan (CPT-11) has been tested as a single agent in several studies, and response rates of 18-23% have been reported in first-line gastric cancer therapy. In the present study we report the safety and efficacy results combining CPT-11 with 5-fluorouracil (5-FU) and folinic acid (FA). Thirty consecutive patients with metastatic gastric cancer, considered in poor clinical condition, were treated with CPT-11 and 5-FU/FA according to the FOLFIRI regimen. All enrolled cases were evaluable for toxicity and drug activity. The main grade 3-4 toxicity (according to the NCI-CTC criteria) was neutropenia (16%, grade 4 in 1 patient); non-hematological grade 3 toxicity consisted mainly in vomiting and diarrhea reported in 1 patient. No treatment-related serious adverse events were observed. Response was obtained in 12 patients (40%), stable disease in 2 patients (7%), while progression was documented in 16 patients (53%). These results are very promising, and suggest that the combination of CPT-11 plus 5-FU/FA is active and well tolerated and can be considered as useful treatment in patients with metastatic gastric cancer in poor clinical condition.
ISSN:0300-8916
2038-2529
DOI:10.1177/030089160609200502